ArticleNPJ Parkinson's disease2026
Associations of DTI-ALPS index and choroid plexus volume with clinical severity across the Parkinson's disease spectrum.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The glymphatic-lymphatic axis: known pathways, open questions, and emerging roles in neurodegeneration.Translational neurodegeneration · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Impaired clearance of pathogenic proteins may contribute to Parkinson's disease (PD) progression, but the clinical relevance of brain clearance-associated processes in humans remains incompletely understood. Using cross-sectional data from 1,861 participants (704 PD, 997 prodromal, 160 healthy controls) in Parkinson Progression Marker Initiative, we investigated whether the magnetic resonance imaging (MRI)-based indirect markers linked to brain clearance-related processes, diffusion tensor imaging analysis along the perivascular space (DTI-ALPS) index and normalized choroid plexus volume (NCPV), are associated with disease stage and motor/non-motor manifestations across the PD spectrum. The ALPS index declined with age, was lower in males, and showed a stepwise reduction from controls to prodromal individuals and PD patients. Clinically, lower ALPS index correlated with greater motor severity in prodromal and PD groups, with stronger associations at advanced stages. Lower ALPS index also correlated with rapid eye movement sleep behavior disorder, cognitive impairment, and depressive symptoms. NCPV showed a complementary trend, demonstrating positive associations with clinical severity measures and a significant negative correlation with the ALPS index. Together, these findings suggest that MRI markers linked to brain clearance processes are associated with clinical progression across the PD continuum and may provide imaging biomarkers relevant to disease staging and pathophysiology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.